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Dynamic Cardiovascular
Risk Assessment in Elderly People
The Role of Repeated N-Terminal
Pro–B-Type Natriuretic Peptide Testing
Christopher R. deFilippi, MD,* Robert H. Christenson, PHD,† John S. Gottdiener, MD,*
Willem J. Kop, PHD,* Stephen L. Seliger, MD, MS‡
Baltimore, Maryland
Objectives This study sought to determine whether serial measurement of N-terminal pro–B-type natriuretic peptide (NT-
proBNP) in community-dwelling elderly people would provide additional prognostic information to that from tra-
ditional risk factors.
Background Accurate cardiovascular risk stratification is challenging in elderly people.
Methods NT-proBNP was measured at baseline and 2 to 3 years later in 2,975 community-dwelling older adults free of
heart failure in the longitudinal CHS (Cardiovascular Health Study). This investigation examined the risk of new-
onset heart failure (HF) and death from cardiovascular causes associated with baseline NT-proBNP and changes
in NT-proBNP levels, adjusting for potential confounders.
Results NT-proBNP levels in the highest quintile (267.7 pg/ml) were independently associated with greater risks of HF (haz-
ard ratio [HR]: 3.05; 95% confidence interval [CI]: 2.46 to 3.78) and cardiovascular death (HR: 3.02; 95% CI: 2.36 to
3.86) compared with the lowest quintile (47.5 pg/ml). The inflection point for elevated risk occurred at NT-proBNP
190 pg/ml. Among participants with initially low NT-proBNP (190 pg/ml), those who developed a 25% increase
on follow-up to 190 pg/ml (21%) were at greater adjusted risk of HF (HR: 2.13; 95% CI: 1.68 to 2.71) and cardio-
vascular death (HR: 1.91; 95% CI: 1.43 to 2.53) compared with those with sustained low levels. Among participants
with initially high NT-proBNP, those who developed a 25% increase (40%) were at higher risk of HF (HR: 2.06; 95%
CI: 1.56 to 2.72) and cardiovascular death (HR: 1.88; 95% CI: 1.37 to 2.57), whereas those who developed a 25%
decrease to 190 pg/ml (15%) were at lower risk of HF (HR: 0.58; 95% CI: 0.36 to 0.93) and cardiovascular death
(HR: 0.57; 95% CI: 0.32 to 1.01) compared with those with unchanged high values.
Conclusions NT-proBNP levels independently predict heart failure and cardiovascular death in older adults. NT-proBNP levels
frequently change over time, and these fluctuations reflect dynamic changes in cardiovascular risk. (J Am Coll
Cardiol 2010;55:441–50) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.069p
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ospitalization in older adults, accounting for more than
75,000 annual hospital admissions (1). Despite declines in
he rates of cardiovascular deaths in the general population,
ore than 80% of cardiovascular deaths occur in elderly
eople (2). Traditional cardiovascular risk factors, although
dept at predicting cardiovascular events in middle-aged
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linical cardiovascular disease is common in elderly
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eople and is associated with an increased risk of cardiovas-
ular events, including HF (4). Furthermore, the develop-
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Dynamic Risk Assessment With NT-proBNP February 2, 2010:441–50ment of new subclinical disease
on repeated measures is associ-
ated with increased risk com-
pared with that for subjects who
remain without identifiable dis-
ease (4).
Blood-based biomarkers pro-
vide an attractive adjunctive meth-
odology for identifying older in-
dividuals at higher risk of adverse
cardiovascular events. Natriuretic
peptide levels (B-type natriuretic
peptide and N-terminal pro–B-
type natriuretic peptide [NT-
proBNP]) are associated with
long-term cardiovascular out-
omes in the general community (5–9). However, it is
ontroversial whether a natriuretic peptide level provides
dditional prognostic information beyond traditional risk
actors in this population (7,10). The CHS (Cardiovascular
ealth Study) trial cohort of elderly participants with
ong-term follow-up, detailed risk factor assessment, and
lectrocardiographic and echocardiographic data allows for
he opportunity to test whether measurement of NT-
roBNP provides independent and additive information.
evertheless, a single measurement of NT-proBNP cannot
eflect change in subclinical disease, and therefore may not
ptimally stratify long-term cardiovascular outcomes (4).
We hypothesized that NT-proBNP, in an ambulatory
lderly population free of HF, would be independently
ssociated with new-onset HF and cardiovascular death
fter adjusting for prevalent comorbidities and cardiovascu-
ar risk factors. Furthermore, we anticipated that serial
easurements of NT-proBNP, as a possible surrogate for
hange in subclinical disease status, identify a dynamic
hange in long-term risk of incident HF and cardiovascular
ortality. Specifically, we hypothesized that individuals
howing increases in NT-proBNP over time would have
levated risks independent of baseline NT-proBNP levels
nd cardiovascular risk factors.
ethods
tudy population. The CHS trial is a multicenter, pro-
pective, observational cohort study of cardiovascular disease
n elderly people. A detailed description of the study
ethods has been published previously (11). For the present
nalysis, participants with prior HF at study entry were
xcluded; HF was identified by self-report and confirmed by
edical record review and/or physician interview as de-
cribed previously (12).
Of the 5,888 CHS trial participants, prevalent HF was
resent in 275 (4.7%), and sufficient serum for NT-proBNP
easurement was available in 4,312 (76.8%) (Fig. 1).
omparing those with and without sufficient sera volumes,
Abbreviations
and Acronyms
CI  confidence interval
ECG  electrocardiogram
HF  heart failure
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
ROC  receiver-operator
characteristichere were no significant differences in demographics andost clinical measures. Modest but statistically significant
ifferences were observed between those with and without
T-proBNP measurements in the frequency of diabetes
17.7% vs. 8.6%), hypertension (59.4% vs. 54.9%), and
urrent smoking (11% vs. 15%).
The CHS trial was approved by the institutional review
oards of the University of Washington and the participat-
ng centers. The current analysis was approved by the
nstitutional review board of the University of Maryland,
altimore.
ssay methods. NT-proBNP was measured in serum col-
ected at baseline in the main CHS trial cohort (1989 to
990) and the supplemental cohort (1992 to 1993). A
econd measure of NT-proBNP was performed on sera
ollected 3 years later for the main cohort (1992 to 1993)
nd 2 years later for the supplemental cohort (1994 to
995). NT-proBNP was measured on the Elecsys 2010
ystem (Roche Diagnostics, Indianapolis, Indiana). The
oefficient of variation for the NT-proBNP assay was 2% to
% during the testing period, and the analytical measure-
ent range for NT-proBNP was 5 to 35,000 pg/ml. All
amples were stored at 70°C to 80°C and were thawed
efore testing (maximum of 3 freeze–thaw cycles). Mea-
urements of NT-proBNP using this assay do not change
fter 5 freeze–thaw cycles (13).
rimary outcomes. Outcomes were incident HF and car-
iovascular mortality. Incident HF events were ascertained
y participant interview at semiannual study visits and
hrough examination of Medicare claims data. Potential HF
vents and determination of cause of death were determined
y an expert adjudication panel (14). Cardiovascular death
as defined as death related to atherosclerotic heart disease
Figure 1 Flow Diagram of CHS Participants
The CHS (Cardiovascular Health Study) trial participants with blood samples avail-
able for N-terminal pro–B-type natriuretic peptide (NT-proBNP) testing at baseline
and follow-up visits. *No study visit or only phone-based visit. HF  heart failure.
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February 2, 2010:441–50 Dynamic Risk Assessment With NT-proBNPfatal myocardial infarction and definite and possible fatal
oronary heart disease), death after cerebrovascular disease
fatal stroke), or death from other atherosclerotic and
ardiovascular diseases as described in detail previously (14).
ther covariates. Clinical characteristics were obtained
rom the initial CHS study visit for each cohort (for the
nalysis of baseline NT-proBNP and outcomes) or at the
tudy visit of the follow-up NT-proBNP measurement (for
he analysis of change in NT-proBNP and outcomes). The
ethodology for assessing cardiovascular risk factors has
een described previously (12).
Coronary heart disease was defined as a history of angina,
yocardial infarction, coronary angioplasty, or coronary
rtery bypass surgery. An electrocardiogram (ECG) was
erformed annually; left ventricular (LV) mass was esti-
ated from the ECG, and major ECG abnormalities,
ncluding atrial fibrillation, were defined according to pre-
iously described methods (15,16). Echocardiography was
erformed in the main cohort in 1989 to 1990 and in both
ohorts in 1995 to 1996. Measures of interest for this
nalysis included left atrial diameter and qualitative left
entricular ejection fraction (LVEF) (normal, borderline, or
bnormal) (17).
tatistical methods. Characteristics by quintile of baseline
T-proBNP were compared by chi-square tests or 1-way
nalysis of variance as appropriate. Cumulative incidence of
F and cardiovascular death were estimated using the
aplan-Meier method and compared with log-rank tests,
nd multivariate analyses were performed using Cox pro-
ortional hazards models. Three sets of adjustment covari-
tes were chosen a priori among factors with an established
Figure 2 Hazard Ratios for New-Onset HF by Decile of NT-proBN
Demographic-adjusted hazard ratios for developing new-onset HF by decile of baseole in predicting cardiovascular events and known or likely co influence natriuretic peptide levels: 1) traditional cardio-
ascular risk factors as defined by the Framingham risk score
18); 2) clinically available risk factors, an expanded set of
actors readily ascertained in a general outpatient clinical
are setting; and 3) measures of cardiac structure (LV mass
y ECG, LVEF, and left atrial diameter by echocardio-
ram). The NT-proBNP was modeled both as a linear
ariable (after logarithmic transformation) and as quintiles.
he optimal threshold of NT-proBNP for increased HF
isk was determined by receiver-operator characteristic
ROC) analyses and by plotting the adjusted risk of HF for
ach decile of NT-proBNP; this threshold was identified at
90 pg/ml, the cut-point separating the seventh from eighth
ecile (Fig. 2). The corresponding sensitivity and specificity
or incident HF were derived by ROC analyses.
The association of change in NT-proBNP with subse-
uent HF and cardiovascular death was examined in 2 ways.
irst, change in NT-proBNP was considered as a categor-
cal predictor. Among those with an initial NT-proBNP of
190 pg/ml, risk of HF and cardiovascular death were
xamined associated with: 1) a decrease in NT-proBNP of
t least 25%; and 2) an increase of at least 25% to a level
190 pg/ml, compared with those with neither change.
he cut-point of 190 pg/ml was derived from the decile
nalysis described above, and the 25% threshold for change
as based on the reported intraindividual variability in
T-proBNP in stable HF patients (19). Likewise, among
hose with a baseline NT-proBNP 190 pg/ml, HF and
ardiovascular death risk were examined associated with:
) a decline of at least 25% to a level 190 pg/ml; and 2) an
ncrease of 25%, compared with those with neither
T-proBNP level. Abbreviations as in Figure 1.P
line Nhange. Second, continuous changes in NT-proBNP levels
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Dynamic Risk Assessment With NT-proBNP February 2, 2010:441–50ere examined using residual change scores, by regressing
he follow-up NT-proBNP measures on the baseline mea-
ures after logarithmic transformation, thereby correcting
hange in NT-proBNP for correlation between baseline and
ollow-up levels (20); this change score was then entered as
he predictor variable in Cox survival models. For both
ategorical and continuous forms of change in NT-
roBNP, Cox regression models were adjusted for the
lapsed time between NT-proBNP measurements, the co-
ariates described above, and interval change in cardiovas-
ular medications and diagnosis of coronary disease. For all
ox models, graphical and formal methods were used to test
he assumption of proportional hazards.
Effect modification by coronary heart disease was exam-
ned by testing multiplicative interaction terms (6). To
xamine model discrimination, the C-statistic was com-
uted for survival regression models with and without
aseline NT-proBNP and interval change (21). The im-
rovement in risk classification by addition of the change in
T-proBNP to risk-factor–adjusted models with only base-
ine NT-proBNP was examined using the net reclassifica-
ion improvement, which represents the net percentage of
ubjects correctly reclassified to risk categories (22). We
ategorized individuals according to model-based risk of
aseline Characteristics of Study Population by NT-proBNP QuintileTable 1 Baseline Characteristics of Study Population by NT-pro
All Q1
Range (pg/ml) 5–47.5
Age (yrs) 72.7 (5.5) 70.5 (4.1)
Male 40.6% 48.1%
African American 15.9% 21.7%
CHD 17.6% 10.0%
Diabetes 17.7% 20.2%
Hypertension 59.4% 50.1%
Smoker 11.1% 12.4%
eGFR (ml/min/1.73 m2) 78.8 (22.7) 83.7 (22.9)
BMI (kg/m2) 26.7 (4.7) 27.6 (4.6)
LDL-C 3.38 (0.91) 3.46 (0.86)
Total cholesterol 5.49 (1.01) 5.59 (0.96)
HDL-C 1.41 (0.41) 1.37 (0.39)
Medications
ACEI 6.6% 6.2%
BB 13.2% 6.5%
Diuretic 24.9% 20.7%
Aspirin 33.8% 31.8%
Major ECG abnormality 28.7% 18.4%
Systolic function
Borderline 5.2% 4.4%
Abnormal 2.7% 0.2%
LV mass (g) by echocardiography (n  2,792)
Women 140.2 (49.0) 133.5 (35.4)
Men 179.8 (54.1) 165.9 (44.1)
Left atrial diameter (cm) 3.78 (0.6) 3.79 (0.61)
CEI  angiotensin-converting enzyme inhibitor; ASA  aspirin; BB  beta-blocker; BMI  body
GFR  estimated glomerular filtration rate; HDL-C  high-density lipoprotein cholesterol; LDL-C 
eptide; Q  quintile; SBP  systolic blood pressure.0-year HF or cardiovascular death of 10%, 10% to 20%, fr 20%. Statistical analysis was performed with Stata
ersion 10 (Statacorp, College Station, Texas); time-
ependent C-statistics were generated using R version
.7.0 (23).
esults
ubject characteristics. The median NT-proBNP was
11.7 pg/ml. Participants were divided into quintiles based
n initial NT-proBNP levels (Table 1). Higher levels were
ssociated with older age, female sex, Caucasian race,
nown coronary heart disease, a lower estimated glomerular
ltration rate, a greater prevalence of major ECG abnor-
alities, increased LV mass, and decreased LVEF. How-
ver, even in the highest quintile of NT-proBNP (267.5
g/ml), more than 80% had a normal LVEF.
utcomes based on the initial NT-proBNP level. Over a
edian follow-up time of 11.9 years, the rates of incident
F and cardiovascular death were 2.6 (95% confidence
nterval [CI]: 2.5 to 2.8) and 2.1 (95% CI: 1.9 to 2.2) per
00 person-years, respectively. Time to incident HF and
ardiovascular death by NT-proBNP quintile is shown in
igures 3A and 3B, respectively. Differentiation of risk
ppeared within the first year and continued throughout
Quintile
Q2 Q3 Q4 Q5 Test for Trend
5–86.8 86.9–143.1 143.2–267.5 267.7–23,445
.1 (4.5) 72.2 (5.0) 73.7 (5.6) 76.1 (6.3) 0.001
8.4% 38.5% 34.7% 43.2% 0.01
7.4% 13.6% 14.5% 12.4% 0.001
2.1% 15.2% 19.4% 31.5% 0.001
6.8% 18.2% 15.2% 18.1% 0.20
4.4% 54.7% 65.2% 72.8% 0.001
2.5% 9.5% 10.8% 10.4% 0.02
.7 (21.6) 79.5 (21.7) 77.4 (23.0) 70.1 (24.7) 0.001
.1 (4.8) 26.7 (4.7) 26.5 (4.7) 25.8 (4.6) 0.001
8 (0.93) 3.38 (0.90) 3.31 (0.91) 3.27 (0.95) 0.001
1 (1.01) 5.51 (1.00) 5.42 (0.99) 5.33 (1.07) 0.001
2 (0.40) 1.43 (0.41) 1.44 (0.43) 1.38 (0.41) 0.4
6.9% 6.0% 6.0% 7.8% 0.40
9.7% 11.1% 16.1% 22.7% 0.001
3.3% 23.3% 27.1% 30.4% 0.001
3.9% 33.4% 34.2% 35.7% 0.10
8.9% 22.7% 30.2% 53.7% 0.001
2.7% 4.5% 5.0% 9.3% 0.001
0.7% 0.8% 2.0% 9.7%
.7 (32.4) 131.6 (35.4) 135.0 (43.6) 145.5 (49.2) 0.001
.2 (41.3) 170.1 (46.5) 187.0 (56.2) 201.8 (65.5) 0.001
7 (0.59) 3.83 (0.61) 3.88 (0.65) 4.14 (0.78) 0.001
dex; CHD  coronary heart disease; DBP  diastolic blood pressure; ECG  electrocardiogram;
nsity lipoprotein cholesterol; LV  left ventricular; NT-proBNP  N-terminal pro–B-type natriureticBNP
47.
71
3
1
1
1
5
1
81
27
3.4
5.6
1.4
2
3
1
130
158
3.7
mass inollow-up for both end points. As shown in Table 2, the
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February 2, 2010:441–50 Dynamic Risk Assessment With NT-proBNPnadjusted risk of incident HF was approximately 4.5-fold
igher and the risk of cardiovascular death was 5.4-fold
igher for subjects in the highest quintile versus the lowest
uintile of NT-proBNP. After adjustment for routinely
vailable clinical factors, the risk remained increased ap-
roximately 3-fold for both end points between the first and
fth quintile. With further adjustment for LV mass, left
trial diameter, and LVEF, hazard ratios comparing the
ighest and lowest quintile of NT-proBNP were 2.62 (95%
I: 2.02 to 3.30) for incident HF and 2.53 (95% CI: 1.92 to
.33) for cardiovascular death. No significant or clinically
mportant differences were observed for the effect of NT-
roBNP on incident HF (p  0.1) or cardiovascular death
p  0.7) between those with and without prevalent
oronary disease.
An inflection for increased risk of incident HF based on
he adjusted hazard ratios by NT-proBNP decile was
dentified between the seventh and eighth deciles (Fig. 2).
herefore, the NT-proBNP value at the 70th percentile
190 pg/ml) was used as a cut-point to separate subjects into
ower- and higher-risk groups. A similar inflection was seen
or cardiovascular death. The associated sensitivity, speci-
city, and positive and negative predictive values for inci-
ent HF during follow-up for this cut-point were 47.6%,
5.6%, 38.4%, and 81.9%, respectively.
rognosis based on change in NT-proBNP level over
ime. Follow-up NT-proBNP samples were available in
,975 subjects, representing 85.8% of the study population
hat was alive, returned for an in-person follow-up visit, and
as without a diagnosis of HF in the interim (Fig. 1).
ubjects with available samples were younger, more often
ale, and less often diabetic (15.6% vs. 20.7%), and had
lightly better renal function and a lower rate of incident HF
nd cardiovascular death (Online Appendix Table 1).
and Cardiovascular Mortalityeart Failure and Cardiovascular Mortality
djusted* Adjusted for Clinically Available Factors†
2 4,129
–1.71) 1.52 (1.43–1.62)
nt Referent
–1.40) 1.10 (0.89–1.37)
–1.65) 1.30 (1.05–1.61)
–2.24) 1.81 (1.46–2.23)
–4.18) 3.05 (2.46–3.78)
–1.82) 1.46 (1.36–1.57)
nt Referent
–1.39) 1.05 (0.80–1.36)
–2.00) 1.40 (1.09–1.80)
–2.81) 1.91 (1.50–2.44)
–4.87) 3.02 (2.36–3.86)
for age, sex, race, smoking, total cholesterol and HDL-C, SBP, and
y major ECG abnormality, use of ACEIs/angiotensin receptor blockers,Figure 3 Kaplan-Meier Plots Based on Quintile of NT-proBNP
Unadjusted Kaplan-Meier plots for (A) time to new-onset HF diagnosis and (B)
time to cardiovascular death based on the quintile (Q) of the baseline visit
NT-proBNP level. Abbreviations as in Figure 1.Association of NT-proBNP and Incident Heart FailureTable 2 Association of NT-proBNP and Incident H
Unadjusted Risk-Factor A
Incident heart failure, n 4,312 4,29
1 log-unit increment 1.78 (1.68–1.88) 1.61 (1.52
Quintiles (pg/ml)
1 (5.0–47.5) Referent Refere
2 (47.5–86.8) 1.12 (0.91–1.39) 1.13 (0.91
3 (86.9–143.1) 1.38 (1.13–1.70) 1.34 (1.08
4 (143.2–267.5) 2.01 (1.65–2.45) 1.83 (1.48
5 (267.7–23,445) 4.53 (3.77–5.46) 3.41 (2.80
Cardiovascular mortality
1 log-unit increment 1.87 (1.77–1.98) 1.71 (1.61
Quintiles
1 Referent Refere
2 1.11 (0.85–1.44) 1.03 (0.77
3 1.63 (1.28–2.08) 1.52 (1.16
4 2.39 (1.90–3.01) 2.16 (1.65
5 5.44 (4.38–6.76) 3.77 (2.91
Values are presented as hazard ratio (95% confidence interval). *Adjusted
hypertension. †Additionally adjusted for diabetes, BMI, CHD, renal function, anjusted for prior stroke.
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Dynamic Risk Assessment With NT-proBNP February 2, 2010:441–50Substantial individual differences in changes of NT-
roBNP were observed during follow-up. Of subjects with
aseline NT-proBNP levels 190 pg/ml, 468 (21%) had a
hange of 25% and to a level 190 pg/ml and 357 (16%)
ad a 25% decrease on the second sample measurement.
or subjects with initial levels 190 pg/ml at baseline, 112
15%) had a 25% decrease to 190 pg/ml and 293 (40%)
ad a 25% increase on the second sample measurement.
haracteristics of participants with respect to change in
T-proBNP levels are shown in Table 3.
Incident rates for new-onset HF and cardiovascular death
ased on change from baseline levels are shown in Figures
A and 4B. Subjects with initially low levels of NT-proBNP
hose level increased at follow-up had higher rates of
ncident HF and cardiovascular death compared with sub-
ects whose NT-proBNP level remained low and unchanged
p  0.001). In contrast, subjects with initially low levels of
T-proBNP whose level decreased 25% had no signifi-
ant difference in outcomes compared with subjects whose
T-proBNP level remained low (Fig. 4, Table 4). Subjects
ith initial NT-proBNP levels 190 pg/ml and who
isplayed a 25% increase had a higher incidence of HF
nd cardiovascular death during follow-up compared with
haracteristics of Participants at Follow-Up NT-proBNP MeasuremeTable 3 Characteristics of Participants at Follow-Up NT-proBNP
Baseline <190 pg/ml (n  2,243)
>25% Decrease
n  357 (16%)
Age (yrs) 73.1 (4.0)
Male 141 (39.5%)
African American 70 (19.6%)
Diabetes 74 (20.7%)
CHD 41 (11.5%)
Hypertension 158 (44.4%)
Major ECG abnormality 55 (21.0%)
BMI (kg/m2) 27.7 (4.6)
eGFR (ml/min/1.73 m2) 71.0 (15.9)
Baseline NT-proBNP 89.1 (59.6–127.6)
ACEI/ARB 43 (12.0%)
BB 23 (6.4%)
Baseline >190 pg/ml (n  732)
Decrease >25% and
<190 pg/ml
n  112 (15%)
Age (yrs) 75.1 (5.0)
Male 32 (28.6%)
African American 23 (20.5%)
Diabetes 18 (16.1%)
CHD 24 (21.4%)
Hypertension 78 (69.6%)
Major ECG abnormality 25 (28.1%)
BMI (kg/m2) 27.7 (5.6)
eGFR (ml/min/1.73 m2) 66.3 (15.0)
Baseline NT-proBNP 251.7 (216.6–302.4)
ACEI/ARB 15 (13.4%)
BB 18 (16.1%)
alues in parentheses are SD or percent.
ARB  angiotensin receptor blocker; other abbreviations as in Table 1.ubjects with initially high levels that remained high but (nchanged. In contrast, subjects with initial levels of NT-
roBNP 190 pg/ml whose levels decreased 25% had a
ignificantly lower incidence of both outcomes compared
ith subjects whose NT-proBNP levels remained high and
nchanged (Fig. 4, Table 4). Furthermore, a signal for
ncreased risk of incident HF with a 25% increase in
T-proBNP level could be seen in subjects with baseline
alues as low as the second quintile (median baseline
oncentration 59.2 pg/ml, median increase 70.5 pg/ml,
nadjusted hazard ratio: 2.70; 95% CI: 1.52 to 4.83). Tests
f effect modification by prevalent coronary heart disease
evealed no significant interactions (p 0.1). Using residual
hange scores, baseline-corrected changes in NT-proBNP
emained significantly predictive for incident HF and car-
iovascular death after adjusting for covariates (Online
ppendix Table 2).
mprovement in prognostic accuracy and reclassification.
he areas under the ROC curves were calculated adjusting
or demographic and cardiovascular risk factors (Table 5).
emographic and cardiovascular risk factors were highly
redictive of incident HF and cardiovascular death. Addi-
ion of baseline and follow-up NT-proBNP increased pre-
ictive accuracy significantly (p  0.05) for both outcomes
Interval Change in NT-proBNPsurement by Interval Change in NT-proBNP
ignificant Increase
 1,418 (63%)
Increase >25% and
>190 pg/ml
n  468 (21%) Test for Trend
3.6 (4.3) 75.7 (5.0) 0.001
52 (38.9%) 184 (39.2%) 0.98
63 (18.6%) 42 (9.0%) 0.001
37 (16.7%) 56 (12.0%) 0.001
98 (14.0%) 124 (26.5%) 0.001
67 (54.2%) 288 (61.5%) 0.001
41 (22.8%) 152 (42.7%) 0.001
7.1 (4.5) 26.3 (4.7) 0.001
0.1 (15.3) 65.7 (16.0) 0.001
0.8 (33.1–93.9) 116.1 (75.9–148.6) 0.001
13 (8.0%) 52 (11.1%) 0.9
33 (9.4%) 85 (18.2%) 0.001
ignificant Decrease
n  327 (45%)
>25% Increase
n  293 (40%)
6.6 (5.6) 78.4 (6.1) 0.001
01 (30.9%) 122 (41.6%) 0.003
36 (11.0%) 27 (9.2%) 0.005
32 (9.8%) 46 (15.7%) 0.51
86 (26.3%) 107 (36.5%) 0.001
15 (65.8%) 193 (66.1%) 0.6
98 (40.0%) 100 (53.5%) 0.001
5.8 (4.6%) 25.9 (4.6) 0.007
3.0 (16.7) 58.7 (17.0) 0.001
6.5 (247.7–595.3) 300.6 (237.5–474.5) 0.007
38 (11.6%) 31 (10.6%) 0.4
51 (15.6%) 65 (22.2%) 0.06nt byMea
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et reclassification improvement was also improved 4.5% to
.9% by the addition of change in NT-proBNP (Online
ppendix Table 3) compared with traditional risk-factor–
djusted models containing baseline NT-proBNP only.
iscussion
ndependent of age, traditional cardiovascular risk factors,
CG, and echocardiographic abnormalities, an elevated
T-proBNP level is a long-term predictor of new-onset
F and cardiovascular death in community-dwelling indi-
iduals age 65 years and older. Furthermore, NT-proBNP
Figure 4 Incident Rates for CV Outcomes Based on Change in
Incident rates for (A) new-onset HF and (B) cardiovascular (CV) death based on ch
in NT-proBNP level is defined among those with a baseline NT-proBNP 190 pg/m
a level 190 pg/ml. Change in NT-proBNP level is defined among those with a ba
pg/ml or an increase of 25%. Abbreviations as in Figure 1.evels frequently are dynamic over time, conferring a change cn risk for subsequent cardiac events concordant with the
irection of change of the biomarker. The NT-proBNP
easurement may be particularly well suited to an elderly
opulation with highly prevalent cardiovascular risk factors.
Assessment of risk for cardiovascular events can be
articularly challenging in elderly people, with less accuracy
ssociated with composite risk scores of traditional cardio-
ascular risk factors, including the Framingham risk score,
nd absent or attenuated risk prediction with the use of
stablished biomarkers such as lipid levels and C-reactive
rotein, compared with the general population (3,6,24,25).
n contrast, a natriuretic peptide level may reflect the
oBNP Level
or absence of change between baseline and follow-up NT-proBNP levels. Change
ither a decrease in NT-proBNP of at least 25% or an increase of at least 25% to
NT-proBNP 190 pg/ml as either a decline of at least 25% to a level 190NT-pr
ange
l as e
selineontributions of multiple cardiac pathologies, including
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Dynamic Risk Assessment With NT-proBNP February 2, 2010:441–50schemia, fibrosis, and hypertrophy, in addition to hemody-
amic stress, such that these biomarkers reflect the overall
urden of clinical and subclinical cardiovascular disease (26).
Two prior studies have shown single measurements of
T-proBNP to independently predict outcomes in elderly
eople (6,9). In the first study, NT-proBNP was a signifi-
ant prognostic factor of cardiovascular events only in
ubjects with known coronary heart disease (6). In contrast,
T-proBNP predicted cardiovascular-related mortality
mong older Swedish men of similar age, including those
ithout coronary heart disease, when combined with mark-
rs of inflammation, renal function, and myocardial necrosis
9). The present results expand on these prior reports by
emonstrating the ability of NT-proBNP to predict both
ncident HF and cardiovascular death in a geographically
nd racially diverse cohort of men and women regardless of
omorbidity and independent of age, as well as echocardio-
raphic and ECG measures of subclinical heart disease.
We also identify for the first time in a community-
welling general population that NT-proBNP levels are
ynamic and that fluctuation reflects a change in risk for
ubsequent cardiovascular events independent of baseline
evel and comorbidity. The concept that fluctuations in
ssociation of Significant Changes in NT-proBNP and Outcomesmong Those Free of HF and With Baseline NT-proBNP <190 pg/mTable 4 Association of Sig fica t Changes in NT-proBNP and OAmong Those Free of HF and With Baseline NT-proBNP
Interval Change in NT-proBNP Una
NT-proBNP 190 pg/ml
Incident HF (439 events) 25% decrease 0.89 (
25% change Re
25% increase to 190 pg/ml 2.41 (
CV death (315 events) 25% decrease 0.92 (
25% change Re
25% increase to 190 pg/ml 2.55 (
NT-proBNP 190 pg/ml
Incident HF (271 events) 25% decrease to 190 pg/ml 0.53 (
25% change Re
25% increase 1.83 (
CV death (224 events) 25% decrease to 190 pg/ml 0.51 (
25% change Re
25% increase 1.94 (
alues are presented as hazard ratio (95% confidence interval). *Age, sex, race, smoking, hypertens
iabetes, CHD (none, prevalent at baseline, or incident during interval between NT-proBNP measu
V mortality additionally adjusted for prior stroke.
CV  cardiovascular; HF  heart failure; other abbreviations as in Tables 1 and 3.
UC of Consecutively Moreomplex Models Predicting HF and CV DeathTable 5 AUC of Consecutively MoreComplex Models Predicting HF and CV Death
Model
AUC
Incident HF CV Death
Demographic 0.66 0.71
 comorbidity* 0.75† 0.77†
 baseline NT-proBNP 0.78† 0.79
 follow-up NT-proBNP 0.80† 0.81†
Similar variables to second model in Table 2. †p 0.05 comparing AUC with more simple nestedf
odel in previous row.
AUC  area under the receiver-operator curve; other abbreviations as in Tables 1 and 4.atriuretic peptide levels outside acute hospitalizations re-
ect a change in the level of risk has been studied previously
n 2 symptomatic patient populations, including those with
cute coronary syndrome presentations and those with
hronic stable HF (27,28). Progression of levels over time
ay reflect the trajectory of progression of subclinical
ardiovascular disease. Even at levels within the normal
ange, an increased NT-proBNP level corresponds with
ncreased risk. We also observed that decreases in levels are
ommon, and in participants with initial levels 190 pg/ml
his reflects a significant decrease in risk of incident HF or
ardiovascular death. This may reflect differences in cardiac
athology leading to the initial elevation.
The present findings indicate the dynamic nature of
ardiovascular risk in elderly people and raise the possibility
hat specific interventions could delay progression to symp-
omatic HF or cardiovascular death. Prior studies targeting
ypertension and sedentary lifestyle have shown success in
educing cardiovascular mortality in elderly people (29,30).
trategies particularly targeting patients identified as higher
isk with initially high levels or those that progressively
ncrease may warrant testing. Early identification of risk in
he subclinical phase of cardiovascular disease may be
articularly critical in elderly people because progression to
ymptomatic HF with associated elevated NT-proBNP
evels may be more resistant to therapy and to strategies
esigned to lower NT-proBNP compared with younger
ndividuals (31). Our analyses suggest that in older adults
ree of HF, a strategy of serial NT-proBNP testing would
orrectly risk-stratify an additional 4.5% to 8% of individ-
als compared with a single NT-proBNP measurement
lone.
tudy limitations. Samples were available in approxi-
ately three-fourths of the cohort at baseline, with one-
>190 pg/mlmes
0 pg/ml and >190 pg/ml
d Traditional Risk Factors* Clinically Available Risk Factors†
.19) 1.00 (0.74–1.35) 0.83 (0.60–1.13)
e Reference Reference
.96) 2.10 (1.69–2.62) 2.13 (1.68–2.71)
.30) 0.99 (0.69–1.40) 0.86 (0.59–1.24)
e Reference Reference
.23) 2.06 (1.60–2.66) 1.91 (1.43–2.53)
.81) 0.51 (0.32–0.79) 0.58 (0.36–0.93)
e Reference Reference
.36) 1.68 (1.30–2.17) 2.06 (1.56–2.72)
.85) 0.49 (0.29–0.84) 0.57 (0.32–1.01)
e Reference Reference
.55) 1.77 (1.33–2.35) 1.88 (1.37–2.57)
P, total cholesterol, and HDL-C. †Additionally adjusted for baseline NT-proBNP, renal function, BMI,
s), and for use of ACE inhibitor/ARB and BBs (both prevalent and interval use). Models predictingl andutco
<19
djuste
0.67–1
ferenc
1.96–2
0.65–1
ferenc
2.01–3
0.34–0
ferenc
1.42–2
0.31–0
ferenc
1.47–2
ion, SB
rementourth of these having no available sera for follow-up
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February 2, 2010:441–50 Dynamic Risk Assessment With NT-proBNPeasures. Subjects with a blood sample at follow-up com-
ared with those without a sample were younger and had a
ower prevalence of clinical risk factors. The differential
bsence of NT-proBNP measures may have introduced bias
nto the estimates of associations with HF and cardiovas-
ular death. The duration of follow-up is a strength of this
tudy, but cardiovascular therapy has changed over time and
t is possible that more ubiquitous use of medications such
s statins could have blunted the predictive value of the
T-proBNP level. Because lipid levels were not indepen-
ently predictive of outcome in this population, this effect is
ikely modest (25,32). These limitations are largely offset by
he representative nature of the CHS trial cohort and the
igh levels of incident HF. The length of follow-up and
igh event rate allowed for a robust multivariate analysis and
he ability to analyze the significance of change in NT-
roBNP levels over longer periods of time than done
reviously in populations with symptomatic cardiovascular
isease (27,28). Lastly, we measured NT-proBNP in sam-
les nearly 20 years old. Given the relatively recent intro-
uction of this assay, we cannot determine with certainty,
hrough repeated measures, the stability of the samples.
owever, stability has been confirmed by repeated measures
s far apart as 2 years, making sample stability less likely to
e an important explanation for between-sample differences
n NT-proBNP measurements (33). Our choice of a 25%
hange in NT-proBNP over time was initially based on
hort-term intraindividual variability in NT-proBNP in
table HF patients. One small study of stable HF patients
onfirms that 1-year intraindividual variability is also ap-
roximately 25% in HF patients with initially low NT-
roBNP levels (34).
onclusions
he NT-proBNP level is a long-term predictor of
ew-onset HF and cardiovascular death in community-
welling elderly people. Furthermore, NT-proBNP levels
requently change substantially over 2 to 3 years. This
hange in level reflects a significant change in patient risk
ndependent of cardiovascular risk factors, ejection frac-
ion, or medication use. Ultimately, NT-proBNP levels
ay guide further diagnostic testing or potential preven-
ive measures to reduce the risk of developing HF or
ying of cardiovascular disease.
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